Immunome reported positive top‑line Phase III results for its oral gamma‑secretase inhibitor, varegacestat, in progressing desmoid tumors — showing an 84% reduction in risk of progression or death versus placebo. The company said it plans to file a New Drug Application (NDA) with the U.S. FDA next year based on the registrational data. The result follows earlier approvals in the space and could deliver a new oral option for an ultra‑rare, hard‑to‑treat tumor type. The readout may reshape competitive dynamics in desmoid tumors and underscores the value of focused rare‑disease programs that can move quickly to regulatory filing after positive registrational data.